Product name | Zidovudine |
CAS No. | 30516-87-1 |
Molecular Formula | C10H13N5O5 |
Molecular Weight | 283.24 |
Quality Standard | 99% up, USP,EP |
Appearance | White powder |
TEST | STANDARD | RESULT |
Appearance: | White powder | Complies |
Loss on drying | ≤ 6.0% | 3.83% |
Heavy metals | < 10ppm | Complies |
As | ≤ 3.0 ppm | Complies |
Pb | ≤ 3.0 ppm | Complies |
Cd | ≤ 0.5 ppm | Complies |
Microbiology |
|
Total plate count | < 1000 cfu/g | 326 cfu/g |
Yeast & Mold | < 100 cfu/g | 28 cfu/g |
E. Coli | Negative | Complies |
S. Aureus | Negative | Complies |
Salmonella | Negative | Complies |
Assay | 995-101% | 99,。5% |
Conclusion | Conforms with USP standard |
|
Function of Zidovudine
Zidovudine is an antiviral drug used in the treatment of patients with AIDS or AIDS-related syndromes and immunodeficiency virus (HIV) infection. It is highly active against retroviruses including human immunodeficiency virus (HIV) in vitro. In virus-infected cells, it is phosphorylated by cellular thymidine kinase to zidovudine triphosphate, which can selectively inhibit HIV reverse transcriptase, leading to the termination of HIV chain synthesis and preventing HIV replication. On March 19, 1987, the US Food and Drug Administration approved the drug for marketing. Zidovudine is the world's first anti-AIDS drug approved by the US FDA.
